IS10: Satellite CME Symposium by Physicians’ Education Resource on behalf of AstraZeneca: Tumor Board: Advances in Managing EGFR-Mutant NSCLC—Applying Evidence Across the Disease Continuum

Details

Room 04

Supported By:  AstraZeneca

Program Description

This live, certified CME satellite symposium, held in conjunction with the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, will feature expert-led presentations and interactive discussions on recent pivotal trial data and future directions for the management of EGFR-mutant NSCLC across the disease continuum. Attendees will gain practical advice for treatment selection and sequencing, as well as available and emerging treatment options for patients with atypical mutations that are resistant to historically used targeted therapies in the standard of care.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

• Discuss current and emerging therapeutic options for first- and second-line treatment of EGFR-mutated NSCLC
• Formulate appropriate strategies for the management of adverse effects related to EGFR targeted therapies in NSCLC
• Develop individualized treatment plans for patients with EGFR-mutant NSCLC by implementing new data and guideline-recommended strategies

Speakers

Moderators
Tina Cascone MD, PhD
The University of Texas MD Anderson Cancer Center
Associate Professor
Houston, TX

David Planchard MD
Institut Gustave Roussy
The Christie NHS Foundation Trust
Head of Thoracic Group
Villejuif, France